UK markets closed

Hercules Capital, Inc. (HTGC)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
19.43+0.13 (+0.67%)
At close: 04:00PM EDT
19.69 +0.26 (+1.34%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close19.30
Open19.42
Bid19.20 x 2200
Ask19.70 x 1800
Day's range19.21 - 19.70
52-week range13.01 - 19.70
Volume1,368,853
Avg. volume932,687
Market cap3.151B
Beta (5Y monthly)N/A
PE ratio (TTM)8.83
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.92 (9.88%)
Ex-dividend date13 May 2024
1y target estN/A
  • Business Wire

    Hercules Capital Reports First Quarter 2024 Financial Results

    SAN MATEO, Calif., May 02, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the first quarter ended March 31, 2024. The earnings release can be accessed at Hercules’ Investor Relations website at https://investor.htgc.com/finan

  • Business Wire

    Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the First Quarter 2024

    SAN MATEO, Calif., April 30, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2024 total cash distribution of $0.48 per share. The following shows the key dates of the first quarter 2024 dis

  • PR Newswire

    SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab

    SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules").